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gate the cost-effectiveness of dermoscopy.
Methods: A MDM, previously constructed to calculate the melanoma burden, was slightly
modified to be suitable for CEAs. Two cohorts of patients entered into the model to calculate
morbidity, mortality and costs. These cohorts were constituted by melanoma patients diag-
nosed by dermatologists adequately, or not adequately, trained in dermoscopy. Effectiveness
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I. Tromme et al. / European Journal of Cancer 67 (2016) 38e45 39quality-adjusted life years (QALYs), a composite measure depending on melanoma-related
morbidity and mortality. Costs included costs of treatment and follow-up as well as costs
of detection in non-melanoma patients and costs of excision and pathology of benign lesions
excised to rule out melanoma.
Results: The result of our analysis concluded that melanoma diagnosis by dermatologists
adequately trained in dermoscopy resulted in both a gain of QALYs (less morbidity and/or
mortality) and a reduction in costs.
Conclusion: This study demonstrates how our MDM can be used in CEAs in the melanoma
detection field. The model and the methodology suggested in this paper were applied to two
cohorts of Belgian melanoma patients. Their analysis concluded that adequate dermoscopy
training is cost-effective. The results should be confirmed by a large-scale randomised study.
ª 2016 Elsevier Ltd. All rights reserved.1. Introduction
The current emergence of numerous new treatments and
diagnostic techniques necessitates policy makers to
simultaneously consider effectiveness and costs. While
health workers naturally go for maximum efficiency,
funds are limited and health care payers are faced with
hard choices. Cost-effectiveness analyses (CEAs) may
help in these choices.
In health economics, effectiveness is oftenmeasured by
a reduction in mortality and/or morbidity. Combining
both is typically expressed as quality-adjusted life years
(QALYs) [1]. To compare two scenarios, a CEA contrasts
the difference between the two in terms of QALYs to their
differences in terms of costs. In order to calculate
morbidity, mortality and costs, it is often not feasible to
follow cohorts for the complete trajectories of each pa-
tient from diagnosis to death. Models are therefore used
to simulate the future of patient cohorts.We recently built
such amodel, further referred to as the ‘melanoma disease
model’ (MDM), to assess the evolution of melanoma
patient cohorts and calculate the melanoma burden in
terms of localised, node and distant metastatic stages [2].
For melanoma detection, dermoscopy is probably the
most studied technique and appears to be widely used
among dermatologists in Western countries [3e5]. A
meta-analysis of nine studies comparing naked-eye ex-
amination with and without dermoscopy concluded that
dermoscopy was more accurate than naked-eye exami-
nation when practitioners had undergone at least mini-
mal training in dermoscopy. The difference was
significant in terms of sensitivity, yet not in terms of
specificity [6]. Nevertheless, dermoscopy showed a better
specificity when used by well-trained and experienced
dermoscopists [7]. In addition, the specificity of dermo-
scopy was indirectly measured through observation of
improvements in the malignant/benign ratio of excised
lesions [8]. A study conducted in 13 countries between
1998 and 2007 demonstrated that clinics with dermo-
scopy perform fewer total number of excisions as
compared to clinics without dermoscopy [9].As dermoscopy improves sensitivity in melanoma
detection, dermoscopy may reduce mortality. Addition-
ally, if dermoscopy decreases specificity, it should reduce
morbidity by avoiding unnecessary excisions. Neverthe-
less, to our knowledge, no study has yet demonstrated
that dermoscopy reduces morbidity and/or mortality.
This paper proposes a CEA of dermoscopy with or
without adequate training based on a slightly modified
version of our MDM applied to two Belgian cohorts
constituted by melanoma patients diagnosed by der-
matologists adequately, or not adequately, trained in
dermoscopy. QALYs and costs of both cohorts are
compared to assess the cost-effectiveness of adequate
dermoscopy training.
2. Material and methods
2.1. The MDM
Fig. 1 shows the MDM previously described in details
[2]. In brief, melanoma patients were set to start at one of
the diagnostic stages and entered into the model for a
certain number of 1-year cycles, until death. The prob-
abilities of moving from one stage to another are called
‘transition probabilities’ (TPs). All TPs were calculated
on a yearly basis, meaning that they were dependent on
the time spent by the patient in the previous stage. Our
model therefore differs from the classical ‘Markov
models’ often used for CEA, for which TPs are assumed
to be time independent [10]. The TPs were based on the
data presented in Leiter et al. [11], Eggermont et al. [12]
and Maio et al. [13]. For this CEA, contrary to the
MDM presented previously [2], we consider that patients
can die from any cause at any age (versus only at the end
of life expectancy in the previous analysis). These TPs to
death from other causes were derived from Belgian
mortality tables and are gender- and age dependent [14].
Melanoma patients from the DEPIMELA (from
“De´pistage” e detection, in French e and “Mela-
noma”) study [15] were included in the present study.
Briefly, the DEPIMELA study was conducted in
Fig. 1. Melanoma disease model. The duration of one cycle was set to 1 year. During each cycle, every patient can stay in the same state or
move to another state following one of the model’s transitions. Transition probabilities (TPs) associated to blue and orange arrows were
estimated using the data from, respectively, Leiter et al. [10] and Eggermont et al. [11]. TPs to death from any cause (green arrows) were
obtained from the Belgian mortality tables [13]. TPs from stage IV to death due to melanoma were based on the results of Maio et al. [12].
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recruited from private and public hospital practices.
The patients were categorised, according to the level of
dermoscopy training undergone by the dermatologist
who took the decision to excise, with little training (less
than 10 h) classified as group A, and adequate training
(over 10 h complemented by self-training) as group B.
Stages of melanoma patients were recorded according
to the ‘tumourenodeemetastasis’ (TNM) staging [16].
These were translated into American Joint Committee
on Cancer (AJCC) 2009 stages [17]. All patients clas-
sified as T1b or higher underwent sentinel node biopsy
(SNB), but their results were not collected. We there-
fore derived the probabilities of having a positive SNB
from the results published by Ross et al. [18]. A sensi-
tivity analysis (SA) excluded the nodular sub-type
melanomas.
2.2. Costs
Costs were assumed to be only direct medical costs
arising to the health care payer (i.e. the health care
system costs and the patients’ personal copayments
combined), according to Belgian guidelines for CEA
[19]. Treatment costs and follow-up costs were assessed
through the 2012e2013 patients who participated in the
health-related quality of life (HRQoL) study described
previously [20]. Briefly, the patients were categorised in
eight groups according to the 2009 AJCC classification(0eIA, IBeII, III and IV), each stage being sub-divided
into treatment and remission phases. In addition to
HRQoL questionnaires, patients were asked to complete
a questionnaire about their personal melanoma-related
costs. The questions covered the external medical con-
sultations and external pharmacist costs. Current
Belgian unit costs are presented in Table 1. We also
included the hospital bill costs for those patients who
received the full treatment or follow-up in the St Luc
hospital. In each of these eight groups, the costs were
estimated based on all patients (if less than 20) or on a
random sample of 20 patients. Given that the HRQoL
study included stage 0eIeII patients for only 2 years,
the costs for the third year were assumed to remain
identical as those of the second year, and from the
fourth year onwards, the mean costs were assessed by
means of expert’s opinion. According to Belgian
guidelines, future costs were discounted at a 3% rate
[19]. Total treatment and follow-up costs were calcu-
lated based on the future history of patients of groups A
and B as predicted by our MDM.
Detection costs were derived from the DEPIMELA
study [15]. These included screening costs and benign
lesion excision costs. The screening costs included the
consultation cost, added to dermoscopy cost when
applicable, for all patients exhibiting neither melanoma
nor suspicious lesions. The costs of excising benign
suspicious lesions included the surgery and pathology
costs.
Table 1
Unit costs in Belgium (2013), expressed in V.
Cost (in V)
Personal costs
General practitioner’s consultation 23.67
Nursing at home 13.78
Psychologist’s consultation 50,00
Physiotherapist’s consultation 21.96
Alternative medicine consultation 50.00
Healing cream 40.12
Bandages 20.00
Antibiotic treatment 10.54
Analgesic treatment 12.23
Anxiolytic treatment 57.76
Support stockings 100.00
Detection costs
Dermatologist’s consultation 28.88
Dermoscopy 6.39
Cutaneous tumour excision with suture 54.1
Cutaneous tumour pathology 62.02
Immunochemistrya 25.41
a We assumed that two immunostains were performed in a number of
benign nevi equivalent to the number of melanomas in each group [30].
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Patients from groups A and B were entered into the
MDM. To calculate QALYs, each year of life from
diagnosis to death had to be weighted by a number be-
tween one (perfect HRQoL) and zero (death), so-called
‘utility’. We used recently published utilities based on EQ-
5D-5L (EuroQol e 5 Dimensions e 5 Levels) instrument
[20]. As stage 0eIeII patients were assumed to exhibit
the same HRQoL as the general population from the
third year after diagnosis onwards, we applied single year
of age EQ-5D-3L Belgian population norms for these
patients [21] to assess their QALYs from the third year
after diagnosis to death. According to Belgian guidelines,
the QALYs were discounted at a rate of 1.5% [19].2.4. Probabilistic sensitivity analysis
To jointly investigate the impact of uncertainty in the
model parameters, a probabilistic sensitivity analysis
(PSA) was performed [22]. The QALY and cost com-
putations were repeated 1000 times considering for each
analysis, random draws for the values of parameters,
from a probability distribution reflecting parameter
uncertainty. Uncertainty was considered for TPs, utili-
ties, hospital costs, personal costs and detection costs.
Probability distributions used were gamma for the TPs
(with parameter values determined based on the confi-
dence interval of the estimated hazard), beta for utilities
(with parameter values based on the observed mean and
standard error of the mean), and gamma for the hospital
costs (idem). Uncertainty for detection costs was
calculated from the number of screening consultations
needed to find a melanoma and the number of benignsuspicious lesions to excise needed to diagnose a mela-
noma for each dermatologist in groups A and B,
respectively. To capture the uncertainty in these pa-
rameters, they were modelled as Poisson distributions
with means corresponding to the observed values. Un-
certainties in the personal costs were modelled in a
similar way, considering binomial distributions for the
proportions of patients who had access to external
consultations with fixed current Belgian unit costs for
those. For each of the 1000 PSA replications, the QALY
and cost differences between both groups were calcu-
lated and plotted on a so-called ‘cost-effectiveness plane’
[1].
3. Results
3.1. Results derived from the DEPIMELA study
During 1 year, 94 melanomas were diagnosed in group
A and 74 in group B. The numbers of melanomas were
higher than those reported in the DEPIMELA study
due to the false-negative melanomas having been
excluded in the previous study due to a different end-
point [15]. All 168 melanoma patients were node nega-
tive on clinical examination. Table 2 presents the patient
characteristics and distribution according to the trans-
lation from TNM classification to AJCC 2009 staging,
SLN result being derived from Ross et al. [18]. The
second part of the table presents the same data ac-
cording to SA excluding the nodular sub-type mela-
nomas. Table 3 displays the number of screened patients
and the number of benign lesions excised in order to find
a melanoma according to the DEPIMELA results and
the costs associated with these screenings and excisions.
3.2. Costs assessments
Hospital costs were obtained from a random sample of
20 patients in each group, except for stage III patients in
treatment (14 patients) and stage IV patients in remis-
sion (11 patients). This resulted in 145 hospital bills to
estimate hospital costs. The patients’ personal medical
costs were based on 253 questionnaire responses. Mean
costs per stage are presented in Table 4.
3.3. CEA planes
Our PSA led to an average decrease in cost of 4420V
(95% credibility interval [CI]: 5821, 2972) and an
average increase in QALY of 2.03 (95% CI: 1.99, 2.07) in
favour of group A. The CEA plane (Fig. 2) confirms
that group B dominates group A, meaning that ‘der-
moscopy performed by adequately trained dermatolo-
gists’ is found to be more effective and less costly than
‘dermoscopy performed by non-adequately trained
dermatologists’. This result is robust, as all the PSA dots
are in the south-east quadrant meaning that for all 1000
Table 2
Melanoma patients from the DEPIMELA study.
Mean age Gender ratio M:F In situ IA IB IIA IIB IIC IIIA IIIB Total
Group A 51.8 0.45 19 53.82 8.85 3.08 2.58 0.45 4.07 2.16 94
Group B 45.6 0.90 28 39.40 3.53 0 0.63 0 1.82 0.62 74
Group A, SA 51.6 0.44 19 52.86 8.85 2.31 1.95 0.45 3.80 1.79 91
Group B, SA 45.6 0.90 28 39.40 3.53 0 0.63 0 1.81 0.62 74
Abbreviations: M: male; F: female; SA: sensitivity analysis excluding nodular melanomas.
Numbers are not whole numbers because tumourenodeemetastasis were translated into probability of American Joint Committee on Cancer
classification according to Ross [18].
Table 3
Number of patients to screen and number of benign lesions to excise per melanoma diagnosed; detection costs per melanoma diagnosed,
expressed in V
Number of
patients to
screen
Costs of
screening
(in V)
Number of
benign lesions
to excise
Costs of
benign lesions
excised (in V)
Total
detection
costs (in V)
Group A 89.94 2597 9.71 1153 3751
Group B 91.30 3220 7.70 920 4140
Table 4
Costs according to American Joint Committee on Cancer stages, excluding screening costs, expressed in V and utilities
Periods Hospital costs Personal costs Utilities
0/IA-T 3 First months 1132 (874e1423) 95 (76e115) 0.687 (0.641e0.731)
0/IA-R 4th to 36th month, per year 280 (171e414) 82 (57e112) 0.809 (0.773e0.843)
0/IA-R 37th month to death, per year 44* 0* 0.809 (0.773e0.843)
IB/II-T 3 First months 3589 (3190e4011) 199 (140e262) 0.579 (0.486e0.670)
IB/II-R 4th to 24th month, per year 1061 (792e1369) 227 (166e293) 0.802 (0.763e0.838)
IB/II-R 37th month to death, per year 44* 0* 0.802 (0.763e0.838)
III-T 3 First months 6840 (5506e8317) 768 (505e1046) 0.535 (0.393e0.674)
III-R From 4th month, per year 1680 (1134e2331) 576 (388e799) 0.703 (0.659e0.745)
IV-T From start of treatment, per year 82,853 (66,301e101,221) 406 (210e628) 0.583 (0.524e0.641)
IV-R From start of remission, per year 2349 (1804e2964) 81 (6e171) 0.796 (0.701e0.877)
*No uncertainty considered (mean costs assessed by means of expert’s opinion).
Observed mean value and 95% credibility intervals (CIs) representing uncertainty in our estimation were reported. These 95% CIs are based on
actual quantiles for hospital costs and utilities and on simulation for personal costs.
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QALYs in group A and costs in group B were lower
than costs in group A. The SA that removed nodular
melanoma from the cohort led to the same conclusions
(Fig. 3). The vertical direction of the ellipse-shaped
cloud in the CE planes indicate that there is more
parametric uncertainty in relation to the costs than
QALY differences between both groups, given the scale
of the axes.
4. Discussion
To the best of our knowledge, this is the first study that
sought to assess the cost-effectiveness of dermoscopy.
This technique has proven to enhance sensitivity when
performed after minimal training, as well as specificity
when performed by well-trained and experienced der-
moscopists. Yet these observations have never been
investigated in a CEA, in which the outcomes were
expressed in QALYs. The study at hand provides an
MDM which could be used to derive QALYs and costsfor any patient cohort, requiring only information on
the stage at diagnosis along with local costs for treat-
ment and follow-up of each melanoma stage, as well as
updated information on TPs if new treatments are
considered.
We use this model to perform a CEA of adequate
training in dermoscopy, entering into the MDM two
cohorts of patients as well as treatment and follow-up
cost data. In addition to these costs, detection costs were
included as part of the melanoma-related costs.
The CEA plane indicated that dermoscopy per-
formed by adequately trained dermatologists dominated
significantly dermoscopy performed by non-adequately
trained dermatologists, meaning that the first situation
was consistently more effective and less costly than the
second. The so-called ‘fast-growing melanomas’
(FGMs) represent, according to some authors, a large
proportion of ‘killer’ melanomas. FGMs frequently
elude early detection due to the difficulty for the patient
and physician, including dermoscopists, to diagnose
them. In addition, these are almost never detected in
Fig. 2. Cost-effectiveness plane. Delta QALY Z QALY B e
QALY A. Delta costs Z costs B e costs A. Each dot represents
for one replication of the probabilistic sensitivity analysis the re-
sults obtained for the difference in QALY per subject (delta
QALY per case) and for the difference in cost per subject (delta
cost per case) for group B minus group A. A positive value for
delta QALY represents an advantage of group B over group A in
terms of effectiveness, while a negative value for delta cost rep-
resents a higher cost for group A compared to group B. Abbre-
viation: QALY, quality-adjusted life year.
Fig. 3. Cost-effectiveness plane, sensitivity analysis excluding
nodular melanomas. Delta QALYZ QALY B e QALY A. Delta
costsZ costs B e costs A. Each dot represents for one replication
of the probabilistic sensitivity analysis the results obtained for the
difference in QALY per subject (delta QALY per case) and for the
difference in cost per subject (delta cost per case) for group B
minus group A. A positive value for delta QALY represents an
advantage of group B over group A in terms of effectiveness, while
a negative value for delta cost represents a higher cost for group A
compared to group B. Abbreviations: QALY, quality-adjusted life
year.
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aggressiveness and the fact that they do not preferen-
tially affect patients at high risk for melanoma [23e25].
As FGMs almost always originate from the nodular
pathological sub-type, we conducted a SA excluding
nodular melanomas. We could, in fact, consider their
diagnosis to be purely a matter of chance, and their
aggressiveness may lead to an artificial and on balance
equal loss of QALYs in groups A and B. The results of
this SA, however, do not change our conclusions.
Our study has some limitations. First, patients were
not randomised and we cannot exclude that the behav-
iour of the patients was influenced by the dermatologist
they chose to consult. As a main example, it is possible
that patients who consulted dermatologists adequately
trained in dermoscopy were more careful with their
moles and consulted faster when a lesion had appeared
or changed. Dermoscopists are also often more moti-
vated to perform total body examinations [26]. Second,
the cohorts included in the MDM are rather small and
the costs are estimated on a sub-optimal number of
patients. Third, our QALY assessment did not include
the decreased HRQoL generated by the surgery of
benign lesions excised to rule out melanomas. Fourth,
our cost assessment did not take into account costsrelated to the dermatologist’s training, nor the patients’
travel costs and the indirect costs related to the loss of
productivity owing to inability to work or death
resulting from melanoma or from undergoing diagnostic
procedures and receiving treatment.
However, despite these limitations, the MDM we
suggest has the advantage of being closer to reality
compared to most models used until now. Indeed, it is as
much as possible informed by empirical studies and in-
cludes time-dependent TPs. Besides dermoscopy, the
MoleMate system is another non-invasive system aimed
at improving melanoma detection in primary care. Due
to its more complex nature, this system is more expen-
sive. A randomised controlled trial has already demon-
strated its efficacy among general practitioners versus
best practice [27]. Nevertheless, when this efficacy has to
be translated in effectiveness and valued in terms of
QALYs for a CEA, one of the main obstacles is the lack
of data with which to assess the evolution of diagnosed
melanomas [28]. The authors of this CEA used a simple
assessment suggested by Losina in a previously pub-
lished CEA of melanoma screening [29]. Based on ex-
perts’ opinion, they predicted a 10% progression rate of
melanoma from one stage to another annually. Our
I. Tromme et al. / European Journal of Cancer 67 (2016) 38e4544MDM could be expected to provide more reliable results
in such CEAs related to melanoma detection.
As a result, this paper provides an opportunity to
discuss the cost-effectiveness of training in dermoscopy,
which should be ideally confirmed with a large multi-
center and randomised study. However, dermoscopy has
become a standard of care in all high-income countries
that would have adequate funds to set up such a study.
It will remain ethically challenging to randomise pa-
tients into groups examined by adequately trained der-
matologists and ‘insufficiently trained’ dermatologists.
Hence, model-based evaluations such as ours will need
to continue providing insights in cost-effectiveness
research. The main interest of this paper therefore re-
sides in its proposal of a new model for conducting CEA
in the melanoma detection field and, in a wider sense, for
all melanoma screening tests or preventive campaigns.
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